Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease
|
|
- Blaise Allison
- 6 years ago
- Views:
Transcription
1 26 ORIGINAL ARTICLE Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease Liyakat Ali Gauri 1, Qadir Fatima 2, Sharanbasu Diggi 3, Asim Khan 4, Ambreen Liyakat 5, BR Ajay 3 Abstract Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis. 1-3 People with rheumatoid arthritis are at increased risk of osteoporosis. Hence this article intends to highlight the importance of BMD measurement in patients with RA as a tool for assessment of disease activity and severity. Objectives: To evaluate Bone Mineral Density in patients of Rheumatoid Arthritis and Co-relate it with severity of disease. Materials and Methods: Hand bone density was measured on the plain radiographs of the right hand using digital x-ray radiogrammetry (Pronosco Xposure System 2.0). This BMD was correlated with markers of disease activity using DAS 28 Scoring system. 4 Results: In our study there were 200 patients with equal number of controls. 70 patients in study group and 131 patients in control group were <45 years old and had normal Z-score while in age group >45 years 26 and 20 cases in study and control groups respectively had their Z-score within normal range. There were total 21 and 2 cases of study and control groups respectively (age <45 years) who had osteoporosis while in age group >45 years 12 and 10 cases in study and control groups respectively had osteopenia. Conculsion: Patients with RA are more susceptible for bone loss in comparison to normal age and gender related subjects. Patients with longer duration and higher disease activity are more susceptible for developing osteopenia and osteoporosis. Occurrence of joint deformities increases with longer disease duration. Limitation of physical activity impairs the bone mineral density. Patient taking anti-rheumatic therapy (steroids and Disease-modifying antirheumatic drugs) are at increased risk of bone loss. All these factors contribute to bone loss independent of each other. Introduction R heumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral Editorial Viewpoint Limitation of physicl activity nd anti-rheumatic drug therapy impairs Bone Mineral Density in RA patients. Seropositive RA patients are more prone to osteopenia and osteoporosis. Decreased BMD is more common in patients with early, active, erosive disease. polyarthritis. It is the most common form of chronic inflammatory arthritis and often results in joint damage and physical disability. Because it is a systemic disease, RA may result in a variety of extra articular manifestations, including fatigue, subcutaneous nodules, lung involvement, pericarditis, peripheral neuropathy, vasculitis, and hematologic abnormalities. 1-3 The incidence of RA increases between 25 and 55 years of age, after which it plateaus until the age of 75 and then decreases. The presenting symptoms of RA typically result from inflammation of the joints, tendons, and bursae. Patients often complain of early morning joint stiffness lasting more than 1 Senior Professor, Department of Medicine, 2 Professor, Department of Pathology, 3 Post graduate Student, Department of Medicine, S.P. Medical College, Bikaner, Rajasthan; 4 Senior Resident, Department of Ophthalmology, SMS College, Jaipur, Rajasthan; 5 Consultant Radiologist, SDMH, Jaipur, Rajasthan Received: ; Revised: ; Accepted:
2 27 1 hour and easing with physical activity. The earliest involved joints are typically the small joints of the hands and feet. The initial pattern of joint involvement may be monoarticular, oligoarticular (2-4 joints), or polyarticular (>5 joints), usually in a symmetric distribution. Some patients with an inflammatory arthritis will present with too few affected joints and other characteristic features to be classified as having RA so-called undifferentiated inflammatory arthritis. Increased bone loss is only part of the story in RA, as decreased bone formation plays a crucial role in bone remodeling at sites of inflammation. Recent evidence shows that inflammation suppresses bone formation. The proinflammatory cytokine Tumor necrosis factor-α plays a key role in actively suppressing bone formation by enhancing the expression of dickkopf-1 (DKK-1). DKK-1 is an important inhibitor of the Wnt pathway, which acts to promote osteoblast differentiation and bone formation. Osteoporosis is a condition in which the bone becomes less dense and more likely to fracture. The World Health Organization (WHO) operationally defines osteoporosis as a bone density that falls 2.5 standard deviations (SD) below the mean for young healthy adults of the same gender also referred to as a T-score of 2.5. Studies have found an increased risk of bone loss in individuals with rheumatoid arthritis. People with rheumatoid arthritis are at increased risk of osteoporosis for many reasons. The glucocorticoids medications often prescribed for the treatment of rheumatoid arthritis can trigger significant bone loss. In addition, pain and loss of joint function caused by the disease can result in inactivity, further increasing osteoporosis risk. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density that is 2.5 standard deviations or more below the mean peak bone mass (average of young, healthy adults) as measured by DXA; the term established osteoporosis includes the presence of a fragility fracture. 8 Aims and Objectives 1. To evaluate bone mineral density in patients of Rheumatoid arthritis and equal number of controls. 2. Correlation of BMD with severity of the disease. Material and Methods The present study was a case control study conducted in the Rheumatology Division, Department of Medicine, S.P. Medical College, Bikaner during July 2009 to January 2012 after explaining the objective of the study and taking an informed consent from the patients or from guardian family members. Hand bone density was measured on the plain radiographs of the right hand using digital x-ray radiogrammetry (Pronosco Xposure System 2.0) a computerized version of the traditional technique of radiogrammetry. A standard x ray image of the hand scanned by an x ray scanner into a PC. In order to estimate the BMD value, the digitized image analysed via PRONOSCO SOFTWARE 5. mean surrogate bone density value was calculated from cortical thickness from regions of interest measured at the center of the second, third, and fourth metacarpals. This surrogate bone density measurement (expressed as grams per square centimeter) was based on measurement of the outer and inner diameter, measuring combined cortical thickness. This BMD was correlated with markers of disease activity using DAS 28 Scoring system 9.Other laboratory investigations (eg. Complete blood count, renal function test, liver function test, random blood sugar, serum lipid profile, thyroid function test, erythrocyte sedimentation rate, Rheumatoid factor, C-reactive protein etc.) were done. Appropriate statistical analysis was applied as and when required using statistical software (SPSS version 10.0). Number of patients: Over 200 controls subjects with no known history of disease and equal number of cases recruited as per the following inclusion and exclusion criteria. Inclusion Criteria Patients of rheumatoid arthritis diagnosed as per American College of Rheumatology (ACR) criteria 1987 were included in the study. Exclusion Criteria 1. All patients of rheumatoid arthritis with association illnesses like malignancy, renal failure, liver failure, bronchial asthma, chronic obstructive pulmonary disease, diabetics, coronary artery disease, hypertension, thyroid disorders, dyslipidemia or any other endocrinopathy excluded from this study. 2. Patients of RA with other connective tissue disorders like scleroderma, systemic lupus erythematosus, poliomyelitis etc. (overlap syndrome) excluded from this study. 3. All pregnant and lactating mothers having RA excluded from this study. 4. All patients of RA who smoke excluded from this study. Observations Mean age in study group was and in control group years. Mean hemoglobin was and in study and control groups respectively. Mean BMD was and in study and control groups respectively while mean T-score was in study group and in control group. Mean Z-score in study group was and in control group
3 28 Table 1: Distribution of cases and controls according to Z-score in relation to age Z Score Age group <45 years >45 years Study group Control group Study group Control group Normal (> -0.99) 70 (56.9) 131 (92.3) 26 (33.8) 20 (34.5) Osteopenia (-1 to -2.49) 32 (26.0) 9 (6.3) 39 (50.6) 28 (48.3) Osteoporosis (< -2.5) 21 (17.1) 2 (1.4) 12 (15.6) 10 (17.2) Total 123 (100) 142 (100) 77 (100) 58 (100) Mean Z-score SD T P < On statistical comparison, the difference was statistically highly significant in BMD, T-score, Z-score between study and control groups (p<0.001) while it was insignificant in age, hemoglobin and platelet count (p>0.05). Among the male, there were total 29 patients each in study and control group who had normal Z-score while among females, 67 and 95 cases in study and control groups respectively had their Z-score within normal range and there were total 22 patients each in study and control group who had osteopenia while among females, 49 and 31 cases in study and control groups respectively had osteopenia. There were total 13 patients each in study and control group who had osteoporosis in male group while among females, 20 and 10 cases in study and control groups respectively had Osteoporosis. On statistical comparison of study vs control groups, there was highly significant difference in Z-score among males and females (p<0.001). There were total 96 cases who had their Z-score within normal range and out of these 96 patients joint deformity was present in 23 patients. Out of these 23 patients 4 had their disease duration <1 years while remaining 19 patients had their disease duration 1-5 years. In osteopenia group, there were total 71 patients were found and out of them joint deformity was present in 39 patients. Out of these 39 patients 30 patients had their disease duration >10 years while 7 patients had their disease duration 1-5 years. One patient each was also found in disease duration groups <1 and >5-10 years. In osteoporosis group, there were total 33 patients were found and out of them joint deformity was present in 23 patients. Out of these 23 patients 18 patients had their disease duration >10 years while 3 patients had their disease duration >5-10 years and 2 patients had their disease duration 1-5 years while no patient was found in disease duration <1 year. There were total 96 cases who had their Z-score within normal range and out of these 96 patients joint deformity was present in 9 males and 17 females. Out of these 39 patients with deformities, 14 were males and 25 were females. In osteoporosis group there were total 33 patients were found and out of them joint deformity was present in 23 patients. Out of these 23 patients 11were males and 12 were females. Rheumatoid factor was positive in total 148 patients out of them 37.2% patients had osteopenia, 20.9% had osteoporosis while in patients with negative rheumatoid factor 30.8% had osteopenia and 3.8% had osteoporosis. On statistical comparison t test was applied and the difference was statistically highly significant between Z-score and rheumatoid factor (p<0.001). Rest all the co relations are depicted and presented in Tables 1-3. Table 2: Distribution of newly diagnosed cases and correlation of their Z-score with disease duration (N=51) Age (yrs.) Sex Z-score Discussion Disease duration (yrs.) Newly diagnosed patients <45 Female Normal <1 13 (56.5) (43.5) Osteopenia <1 1 (33.3) (33.3) > >10 1 (33.3) Osteoporosis < (100) Male Normal <1 6 (85.7) (14.3) Osteopenia 0 Osteoporosis 0 >45 Female Normal <1 3 (37.5) (62.5) Osteopenia <1 3 (100) >1 0 Osteoporosis < >10 1 (100) Male Normal <1 1 (25) (75) Osteopenia 0 Osteoporosis 0 Osteoporosis and fragilityrelated fractures are one of the most common complications seen in patients with RA and dramatically affect quality of life 6. The present study was designed to evaluate BMD changes in patients with RA, as well as the effect of severity and drugs (steroids and Diseasemodifying antirheumatic drugs) on these changes. In our study, there were 200 patients with equal number of controls. There were total 70 patients in study group and 131 patients in control group who
4 29 Table 3: Distribution of cases according to Z-Score in relation to disease duration and rheumatoid nodules Z Score Duration of disease group (years) Rheumatoid nodules Total < >5-10 >10 Present Absent Normal (> -0.99) 23 (85.2) 67 (77.9) 3 (30) 3 (3.9) 3 (50) 93 (47.9) 96 (48) Osteopenia (-1 to -2.5) 4 (14.8) 16 (18.6) 4 (40) 47 (61) 3 (50) 68 (35.1) 71 (35.5) Osteoporosis (< -2.5) 0 3 (3.5) 3 (30) 27 (35.1) 0 33 (17) 33 (16.5) Total Mean SD t P <0.001 HS 0.478NS had their age <45 years had normal Z-score while in age group >45 years 26 and 20 cases in study and control groups respectively had their Z-score within normal range. There were total 32 and 9 cases of study and control groups respectively (age <45 years) who had osteopenia while in age group >45 years 39 and 28 cases in study and control groups respectively had osteopenia. There were total 21 and 2 cases of study and control groups respectively (age <45 years) who had osteoporosis while in age group >45 years 12 and 10 cases in study and control groups respectively had osteopenia. On statistical comparison of study vs control groups, there was highly significant difference in Z-score in age <45 years group and in age group >45 years the difference of Z-score between study and control group was insignificant (p>0.05). There were total 51 newly diagnosed cases. There was no specific treatment history in these patients. On the basis of duration of symptoms, patients were divided into 4 groups i.e. <1, 1-5, >5-10 and >10 years. On the basis of age we divided patients into two groups i.e. <45 and >45 years. Among females there were total 40 newly diagnosed cases out of them 28 were from age group <45 years while remaining 12 cases were from >45 years of age group. Out of total 28 patients who had their age group <45 years 23 patients who had their Z-score within normal range and out of these 23 patients 13 were from disease duration <1 years while remaining 10 patients were from disease duration 1-5 years. There were total 12 females who had their age >45 years out of them 8 females had their Z-score within normal range and out of them 3 were from disease duration <1 years and 5 were from disease duration 1-5 years. Out of remaining 4 females, 3 had osteopenia and 1 had osteoporosis and they came from disease duration group <1 years and >10 years respectively. Among males there were total 11 newly diagnosed cases out of them 7 were from age group <45 years while remaining 4 cases were from >45 years of age group. Out of total 7 patients who had their age group <45 years all had their Z-score within normal range and disease duration <5 years. There were total 4 males who had their age >45 years all of these patients had their Z-score within normal and disease duration <5 years. This observation supported the fact that patients with RA are more susceptible for bone loss in comparison to normal age and gender related subjects. These findings are in agreement with those of Brand et al 10 who reported that patients with RA have a higher risk of low BMD than normal ageand gender matched populations. Similarly, a study reported by Kim et al 11 showed an increased risk of osteoporotic fractures in RA patients in all age groups, regardless of gender, and at various anatomical sites compared with individuals without RA. In contrast, Curtis et al 10 found that the proportion of their RA patients meeting t score criteria for osteoporosis (t score <-2.5 at either the lumbar spine or femoral neck) was only 4%, and Yoon et al1 5 reported that 52% of their patients with early-onset RA had osteoporosis and 39% were classified as having osteopenia. Our results are also consistent with those of Güler-Yüksel et al 11 who reported that RA patients with early, active, erosive disease and a positive rheumatoid factor had more aggressive joint disease and decreased BMD. Laan et al 12 PLAN concluded that BMD may be affected in patients with recent onset rheumatoid arthritis by disease dependent mechanism. Kim et al 9 also observed an increased risk of osteoporosis associated with a positive RF and elevated acute phase reactants, although this was not statistically significant. While Solomon et al. 13 have found that BMD at the total hip was significantly lower in rheumatoid factor-positive women than in rheumatoid factor-negative women. However, values at the lumbar spine were almost identical for rheumatoid factor-positive and -negative women. Conculsion Patients with RA are more susceptible to bone loss in comparison to normal age and gender related subjects. Patients with longer duration of disease are more susceptible for developing osteopenia and osteoporosis.
5 30 Patients with higher disease activity are more susceptible for bone loss. Occurrence of joint deformities increases with longer disease duration. Patients who test positive for rheumatoid factor are also more prone to osteopenia and osteoporosis. Limitation of physical activity impairs the bone mineral density. Patient taking anti rheumatic therapy (steroids and Disease-modifying antirheumatic drugs) are at increased risk of bone loss. All these factors contribute to bone loss independent of each other emphasizing the initiation of osteo-protective therapy in rheumatoid arthritis patients as soon as possible. References 1. Felson DT et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 1009; 11: Goldring SR, Goldring MB. Eating bone or adding it: The Wnt pathway decides. Nat Med 207; 13: The Disease Activity Score and the EULAR response criteria- J. Fransen, P.L.C.M. van Riel Radboud University Nijmegen Medical Centre, Department of Rheumatology. Clin Exp Rheumatol 2005; 23(Suppl. 39):S93-S Peter E. Lipsky. Rheumatoid arthritis. Harrison s Principles of Internal Medicine, 17th Edition - Anthony Fauci et al(eds). New York: McGraw-Hill, Medical Pub. Division.2008.Page no WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series 1994; 843: Neogi T. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: Brand C, Lowe A, Hall S. The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis. BMC Musculoskelet Disord 2008; 9: Kim SY, Schneeweiss S, Liu J, et al. Risk of osteoporotic fracture in a large populationbased cohort of patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12:R Bonjour JP. Dietary protein: An essential nutrient for bone health. Journal of the American College of Nutrition 2005; 24(6Suppl):526S 536S. 11. Turesson C et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009; 11: Solomon DH, Finkelstein JS, Shadick N, et al. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis: The Osteoporosis in Rheumatoid Arthritis (OPiRA) Cohort Study. Arthritis Rheum 2009; 60:
EFFECT OF INTRAVENOUS ZOLENDRONIC ACID ON BONE MINERAL DENSITY IN POST MENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY OF NORTH WEST PART OF RAJASTHAN
International Journal of Advanced Research and Review www.ijarr.in EFFECT OF INTRAVENOUS ZOLENDRONIC ACID ON BONE MINERAL DENSITY IN POST MENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY OF NORTH WEST PART
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationBone Mineral Density Changes in Patients with Recent-Onset Rheumatoid Arthritis
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Bone Mineral Density
More informationEtiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationAre glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?
ORIGINAL ARTICLE Korean J Intern Med 2014;29:509-515 Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? Joo-Hyun
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationComparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis
Original Article Comparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis Ali M.E. Yousef 1, Fatemah A. Elshabacy 2, Sherry K. Abdelrahman
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationRheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)
Rheumatoid Arthritis Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904) 503-6999. 1 Disclosures Speaker Bureau: Abbvie 2 Objectives Better understand the pathophysiology
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationMichael Ziegelasch 1*, Kristina Forslind 2,3, Thomas Skogh 1, Katrine Riklund 4, Alf Kastbom 1 and Ewa Berglin 5
Ziegelasch et al. Arthritis Research & Therapy (2017) 19:195 DOI 10.1186/s13075-017-1403-0 RESEARCH ARTICLE Open Access Decrease in bone mineral density during three months after diagnosis of early rheumatoid
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic,
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationERROR CORRECTION FORM
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Registry Use Only Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic, syngeneic unrelated related
More informationREFERRAL GUIDELINES: RHEUMATOLOGY
Outpatient Page 1 1 REFERRAL GUIDELINES: RHEUMATOLOGY Date of birth Demographic Contact details (including mobile phone) Clinical Reason for referral Duration of symptoms Essential Referral Content Referring
More informationInflammatory rheumatic diseases
Learning objectives Inflammatory rheumatic diseases Bruce Kidd Barts & The London, Queen Mary, University of London To understand: 1. prevalence and range of the rheumatological s 2. clinical features
More informationSystemic forms of stiffness
Systemic forms of stiffness ANNA LITWIC CONSULTANT RHEUMATOLOGIST SALISBURY DISTRICT HOSPITAL CLINICAL RESEARCH FELLOW MRC LIFECOURSE EPIDEMIOLOGY UNIT Overview Rheumatoid arthritis Know it when you see
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationwww.fisiokinesiterapia.biz Peak onset between 20 and 30 years Form of spondyloarthritis (cause inflammation around site of ligament insertion into bone) and association with HLA-B27 Prevalence as high
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79. ISSN (e)-37-176x ISSN (p) - DOI: https://dx.doi.org/.183/jmscr/v6i1.18 A Study on Pulmonary Function Test in Patients
More informationClinical Study Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women
International Endocrinology Volume 3, Article ID 895474, 5 pages http://dx.doi.org/.55/3/895474 Clinical Study Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women Na Li, Xin-min
More informationJuvenile Idiopathic Arthritis in Adults: Long-Term Observation of Ukrainian Patients
Archive of Clinical Medicine 2017 Vol. 23, Issue 1, E201715 DOI: 10.21802/acm.2017.1.5 Research Article Juvenile Idiopathic Arthritis in Adults: Long-Term Observation of Ukrainian Patients Marta Dzhus
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOriginal Article Clinical Registry For Rheumatoid Arthritis Pak Armed Forces Med J 2017; 67 (2):
Open Access Original Article Clinical Registry For Rheumatoid Arthritis Pak Armed Forces Med J 2017; 67 (2): 317-21 CLINICAL REGISTRY FOR RHEUMATOID ARTHRITIS; A PRELIMINARY ANALYSIS Amer Fakhr, Farzana
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationPolymyalgia rheumatica and giant cell arteritis
Polymyalgia rheumatica and giant cell arteritis What is polymyalgia rheumatica? Polymyalgia rheumatica is a rheumatic disorder associated with moderate-to-severe musculoskeletal pain and stiffness in the
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationChapter 8: Exercise for Those with Disorders of the Skeletal System
Chapter 8: Exercise for Those with Disorders of the Skeletal System Williamson, P. (2010). Exercise for Special Populations. Baltimore, MD: Lippincott Williams & Wilkins. Bone tissue Classified as compact
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationWhat is Axial Spondyloarthritis?
Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy
More informationBone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?
Scan for mobile link. Bone Densitometry What is a Bone Density Scan (DXA)? Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationImpact of Chronic Conditions on Health-Related Quality of Life
BURDEN OF ILLNESS Overview Impact of Chronic Conditions on Health-Related Quality of Life Chronic joint pain conditions have an important impact on health-related quality of life Note: a larger negative
More informationOPMED APPLICATION FORM FOR Chronic Disease List Conditions (CDL) and other Chronic Conditions
OPMED APPLICATION FORM FOR Chronic Disease List Conditions (CDL) and other Chronic Conditions ATTENDING MEDICAL PRACTICIONER TO KINDLY COMPLETE THE RELEVANT SECTIONS AND RETURN ALL PAGES TO: PO Box 8796,
More informationCHAPTER 6 MUSCULOSKELETAL SYSTEM DISEASES, DISORDERS, AND DIAGNOSTIC TERMS. Ms. Doshi
CHAPTER 6 MUSCULOSKELETAL SYSTEM DISEASES, DISORDERS, AND DIAGNOSTIC TERMS Ms. Doshi Worksheet 1 pp 154-156 Review Exercises Infections Disease cellulitis myocellulitis osteitis osteomyelitis osteochondritis
More informationGLUCOCORTICOIDS SUPpress
ORIGINAL INVESTIGATION Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis Results From a Randomized Placebo-Controlled Trial Glenn Haugeberg, MD, PhD; Anders Strand; Tore
More informationA Study of Genetic Markers in Patients of Rheumatoid Arthritis and their Co-Relation with Severity of the Disease
2 ORIGINAL ARTICLE A Study of Genetic Markers in Patients of Rheumatoid Arthritis and their Co-Relation with Severity of the Disease Gauri Liyakat Ali, Suman Kapur 2, Sai Chinmayi, Qadir Fatima 4, Harshal
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationABSTRACT. increasing anti-ccp2 antibody concentrations. Associations between BMD and anti-ccp2 antibody status and titer were
Adv Ther (2018) 35:232 242 https://doi.org/10.1007/s12325-017-0657-x ORIGINAL RESEARCH Association of Low Bone Mineral Density with Anti- Citrullinated Protein Antibody Positivity and Disease Activity
More informationEssential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT
Essential Rheumatology Dr Ellen Bruce Consultant Rheumatologist CMFT Saving the best for last! Apparently people recall best the first and last thing they re told. Far too difficult to include everything.
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Contents Introduction...3 What is rheumatoid arthritis?...4 Symptoms of rheumatoid arthritis... 5 What causes rheumatoid arthritis?... 10 The role of genes and family
More informationTo understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis.
Nutrition Aspects of Osteoporosis Care and Treatment t Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, OH. Objectives To understand bone growth and development across the lifespan.
More informationOriginal Research Article. Raj Kumar Bhimwal 1, Mohan Makwana 2 *, Harish Sanawadiya 1, Ratan Lal Bhati 2
International Journal of Advances in Medicine Bhimwal RK et al. Int J Adv Med. 2017 Aug;4(4):952-958 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20172568
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationJMSCR Vol 05 Issue 09 Page September 2017
www.jmscr.igmpublication.org Impact Factor 5.4 Index Copernicus Value: 71.5 ISSN (e)-2347-176x ISSN (p) 2455-45 DOI: https://dx.doi.org/.1535/jmscr/v5i9.11 Prevalence of Hematological Manifestations in
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationEsther Briganti. Fetal And Maternal Health Beyond the Womb: hot topics in endocrinology and pregnancy. Endocrinologist and Clinician Researcher
Fetal And Maternal Health Beyond the Womb: hot topics in endocrinology and pregnancy Esther Briganti Endocrinologist and Clinician Researcher Director, Melbourne Endocrine Associates Associate Professor,
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationLOVE YOUR BONES Protect your future
www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women
More informationFractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases
Financial Disclosures Fractures: Epidemiology and Risk Factors Research grants, speaking or consulting: Amgen, Lilly, Merck, Novartis, Radius Dennis M. Black, PhD Department of Epidemiology and Biostatistics
More informationCase reports CASE 1. A 67-year-old white man had back pain since the age. our clinic several years later with progressive symptoms.
Annals of the Rheumatic Diseases, 1982, 41, 574-578 Late-onset peripheral joint disease in ankylosing spondylitis MARC D. COHEN AND WILLIAM W. GINSBURG From the Division ofrheumatology and Internal Medicine,
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationKelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition
Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationDisclosures Fractures:
Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Research Funding: GlaxoSmithKline, Merck Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Fracture incidence
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationWhen is it Rheumatoid Arthritis When to Refer
When is it Rheumatoid Arthritis When to Refer Nancy A. Brown, DO Spring 2015 When is it Rheumatoid Arthritis When to Refer Learning objectives To review the definition and epidemiology of Rheumatoid Arthritis
More informationMeasuring Bone Mineral Density
Measuring Bone Mineral Density Osteoporosis Screening by Pharmacists 9/20/06 Don Downing Institute for Innovative Pharmacy Practice Today s Topics What is osteoporosis? What causes osteoporosis? Screening
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationBeyond the T-score: New Thinking in Osteoporosis 2
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/beyond-the-t-score-new-thinking-in-osteoporosis-
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationHIV and your Bones Osteopenia and Osteoporosis
Osteopenia and Osteoporosis Background information For reasons not yet fully understood, higher rates of bone disease are starting to be seen in people living with HIV. These bone diseases include osteopenia
More informationUpdate - Imaging of the Spondyloarthropathies. Spondyloarthropathies. Spondyloarthropathies
Update - Imaging of the Spondyloarthropathies Donald J. Flemming, M.D. Dept of Radiology Penn State Hershey Medical Center Spondyloarthropathies Family of inflammatory arthritides of synovium and entheses
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationJuvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA) Kaveh Ardalan, MD, MS Division of Rheumatology Ann & Robert H. Lurie Children s Hospital of Chicago Assistant Professor, Pediatrics and Medical Social Sciences Northwestern
More informationUnderstanding Osteoporosis
Understanding Osteoporosis Professor Juliet E. Compston Published by Family Doctor Publications Limited in association with the British Medical Association IMPORTANT NOTICE This book is intended not as
More informationAUTOIMMUNITY CLINICAL CORRELATES
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationAUTOIMMUNITY TOLERANCE TO SELF
AUTOIMMUNITY CLINICAL CORRELATES Pamela E. Prete, MD, FACP, FACR Section Chief, Rheumatology VA Healthcare System, Long Beach, CA Professor of Medicine, Emeritus University of California, Irvine Colonel
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More information